Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05089734 · ClinicalTrials.gov registry record · Phase 3
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 3
- Development phase
- 603
- Enrollment target
- 20
- Study locations
NCT05089734 is a Phase 3 study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 603 participants, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 20 study locations across 15 states.
The verdict
NCT05089734, a Phase 3 study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 603 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL Sacituzumab Govitecan-hziy (SG)
Study Locations (20)
Florida
- Florida Cancer Specialists (Administration and Drug Shipment) - Fort Myers
- Woodlands Medical Specialists, PA - Pensacola
- Florida Cancer Specialists - St. Petersburg
- Florida Cancer Specialists - West Palm Beach
Illinois
- University of Chicago Medical Center - Chicago
- Illinois Cancer Specialists - Niles
New York
- Broome Oncology, LLC - Johnson City
- Stony Brook Cancer Center - Stony Brook
Alaska
- Alaska Oncology and Hematology, LLC. - Anchorage
Arizona
- USOR - Arizona Oncology Associates Tucson - Wilmot - Tucson
California
- Beverly Hills Cancer Center - Beverly Hills
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
Iowa
- Siouxland Regional Cancer Center dba June E. Nylen Cancer Center - Sioux City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 603 participants |
| Start Date | 2021-11-17 |
| Est. Completion | 2026-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05089734
The ClinicalTrials.gov registry entry for NCT05089734 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 603 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT05089734 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Florida, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05089734 about?
NCT05089734 is a clinical study titled "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". The goal of this clinical study is to compare the study drug, sacituzumab govitecan-hziy (SG), versus docetaxel in participants with advanced or metastatic (cancer that has spread) non-small cell lung cancer (NSCLC).
What is the current status of trial NCT05089734?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 603 participants. The study started on 2021-11-17. Estimated completion is 2026-01.
What conditions does trial NCT05089734 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05089734?
The interventions under investigation include: Docetaxel (DRUG), Sacituzumab Govitecan-hziy (SG) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05089734?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05089734 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.